Neoadjuvant chemotherapy for advanced ovarian cancer

E. Surwit, J. Childers, I. Atlas, M. Nour, Kenneth D Hatch, A. Hallum, David S Alberts

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy with cisplatin or carboplatin was administered to 29 patients with advanced ovarian carcinoma prior to their undergoing definitive cytoreductive surgery. Twenty-eight patients had ascites, eight had pleural effusion, and 16 had extensive upper abdominal disease on computerized tomography scan. The CA125 response to neoadjuvant chemotherapy was highly predictive of survival (P<0.0005). A 2-log decrease in CA125 prior to surgery resulted in a median survival of 37 months, while patients with less than a 1-log response in CA125 had a survival of 18 months. Bowel resection after neoadjuvant chemotherapy did not benefit patients, as their survival (17 months) was identical to that of patients who were nonresectable and did not undergo any cytoreductive surgery. Neoadjuvant chemotherapy offers patients with suboptimal ovarian cancer the same survival as primary cytoreductive surgery with interval debulking, yet with only one operative procedure.

Original languageEnglish (US)
Pages (from-to)356-361
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume6
Issue number5
DOIs
StatePublished - 1996

Fingerprint

Ovarian Neoplasms
Drug Therapy
Survival
Carboplatin
Operative Surgical Procedures
Pleural Effusion
Ascites
Cisplatin
Tomography
Carcinoma

Keywords

  • CA125
  • chemosensitive
  • CT scan
  • debulking
  • neoadjuvant
  • ovarian

ASJC Scopus subject areas

  • Cancer Research
  • Obstetrics and Gynecology
  • Oncology

Cite this

Neoadjuvant chemotherapy for advanced ovarian cancer. / Surwit, E.; Childers, J.; Atlas, I.; Nour, M.; Hatch, Kenneth D; Hallum, A.; Alberts, David S.

In: International Journal of Gynecological Cancer, Vol. 6, No. 5, 1996, p. 356-361.

Research output: Contribution to journalArticle

Surwit, E. ; Childers, J. ; Atlas, I. ; Nour, M. ; Hatch, Kenneth D ; Hallum, A. ; Alberts, David S. / Neoadjuvant chemotherapy for advanced ovarian cancer. In: International Journal of Gynecological Cancer. 1996 ; Vol. 6, No. 5. pp. 356-361.
@article{3af94d12e5c04539b229625ea7376f3d,
title = "Neoadjuvant chemotherapy for advanced ovarian cancer",
abstract = "Neoadjuvant chemotherapy with cisplatin or carboplatin was administered to 29 patients with advanced ovarian carcinoma prior to their undergoing definitive cytoreductive surgery. Twenty-eight patients had ascites, eight had pleural effusion, and 16 had extensive upper abdominal disease on computerized tomography scan. The CA125 response to neoadjuvant chemotherapy was highly predictive of survival (P<0.0005). A 2-log decrease in CA125 prior to surgery resulted in a median survival of 37 months, while patients with less than a 1-log response in CA125 had a survival of 18 months. Bowel resection after neoadjuvant chemotherapy did not benefit patients, as their survival (17 months) was identical to that of patients who were nonresectable and did not undergo any cytoreductive surgery. Neoadjuvant chemotherapy offers patients with suboptimal ovarian cancer the same survival as primary cytoreductive surgery with interval debulking, yet with only one operative procedure.",
keywords = "CA125, chemosensitive, CT scan, debulking, neoadjuvant, ovarian",
author = "E. Surwit and J. Childers and I. Atlas and M. Nour and Hatch, {Kenneth D} and A. Hallum and Alberts, {David S}",
year = "1996",
doi = "10.1046/j.1525-1438.1996.06050356.x",
language = "English (US)",
volume = "6",
pages = "356--361",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for advanced ovarian cancer

AU - Surwit, E.

AU - Childers, J.

AU - Atlas, I.

AU - Nour, M.

AU - Hatch, Kenneth D

AU - Hallum, A.

AU - Alberts, David S

PY - 1996

Y1 - 1996

N2 - Neoadjuvant chemotherapy with cisplatin or carboplatin was administered to 29 patients with advanced ovarian carcinoma prior to their undergoing definitive cytoreductive surgery. Twenty-eight patients had ascites, eight had pleural effusion, and 16 had extensive upper abdominal disease on computerized tomography scan. The CA125 response to neoadjuvant chemotherapy was highly predictive of survival (P<0.0005). A 2-log decrease in CA125 prior to surgery resulted in a median survival of 37 months, while patients with less than a 1-log response in CA125 had a survival of 18 months. Bowel resection after neoadjuvant chemotherapy did not benefit patients, as their survival (17 months) was identical to that of patients who were nonresectable and did not undergo any cytoreductive surgery. Neoadjuvant chemotherapy offers patients with suboptimal ovarian cancer the same survival as primary cytoreductive surgery with interval debulking, yet with only one operative procedure.

AB - Neoadjuvant chemotherapy with cisplatin or carboplatin was administered to 29 patients with advanced ovarian carcinoma prior to their undergoing definitive cytoreductive surgery. Twenty-eight patients had ascites, eight had pleural effusion, and 16 had extensive upper abdominal disease on computerized tomography scan. The CA125 response to neoadjuvant chemotherapy was highly predictive of survival (P<0.0005). A 2-log decrease in CA125 prior to surgery resulted in a median survival of 37 months, while patients with less than a 1-log response in CA125 had a survival of 18 months. Bowel resection after neoadjuvant chemotherapy did not benefit patients, as their survival (17 months) was identical to that of patients who were nonresectable and did not undergo any cytoreductive surgery. Neoadjuvant chemotherapy offers patients with suboptimal ovarian cancer the same survival as primary cytoreductive surgery with interval debulking, yet with only one operative procedure.

KW - CA125

KW - chemosensitive

KW - CT scan

KW - debulking

KW - neoadjuvant

KW - ovarian

UR - http://www.scopus.com/inward/record.url?scp=0029738072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029738072&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.1996.06050356.x

DO - 10.1046/j.1525-1438.1996.06050356.x

M3 - Article

VL - 6

SP - 356

EP - 361

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 5

ER -